Victory Capital Management
ADCT icon

Victory Capital Management’s ADC Therapeutics ADCT Stock Holding History

Victory Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,379
Closed -$556K – 2741
2020
Q4 		$556K Sell
17,379
-1,242
-7% -$40.7K ﹤0.01% 2027
2020
Q3 		$614K Sell
18,621
-7,918
-30% -$343K ﹤0.01% 1887
2020
Q2 		$1.24M Buy
+26,539
New +$1.01M ﹤0.01% 1629

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Victory Capital Management's ADCT Position: Q1 2021 in Review

Victory Capital Management sold out of ADC Therapeutics (ADCT) in Q1 2021, closing a stake of 17,379 shares — an estimated $556K sold.

Victory Capital Management first reported a position in ADCT in Q2 2020 and held it in 3 quarters. The position peaked at $1.24M in Q2 2020. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2021.

  • Victory Capital Management reported no remaining ADC Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Victory Capital Management sold 17,379 ADC Therapeutics shares in Q1 2021, an estimated $556K.
  • Victory Capital Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 3 quarters.
  • Victory Capital Management's ADC Therapeutics position peaked at $1.24M in Q2 2020.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2021.

Based on Victory Capital Management's 13F filing for Q1 2021, filed 4 May 2021.